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Abstract
Background: Multiple sclerosis (MS) is the endpoint of a complex and still poorly understood process which
results in inflammation, demyelination and axonal and neuronal degeneration. Since the first description of MS,
psychological stress has been suggested to be one of the trigger factors in the onset and/or relapse of symptoms.
However, data from animal models of MS, such as experimental autoimmune encephalomyelitis (EAE) are
inconsistent and the effect of stress on EAE onset and severity depends on duration and time of application of the
stress protocol and the underlying mechanisms.
Methods: Dark Agouti rats were inoculated with MOG/CFA to induce EAE, and an immobilisation stress protocol
with two different durations (12 and 21 days, starting at the moment of MOG-inoculation) was applied in order to
analyse the effect of stress on disease onset and neuroinflammation.
Results: Twelve days of stress exposure increased EAE clinical score in Dark Agouti rats. In addition, these animals
presented higher levels of MMP-9 and proinflammatory PGE2 in spinal cord. In contrast, animals chronically
exposed to stress (21 days) showed a significantly lower incidence of EAE clinical signs and reduced myelin loss,
leukocyte infiltration and accumulation of inflammatory/oxidative mediators in spinal cord. Interestingly, chronically
stressed animals showed a parallel increase in levels of the anti-inflammatory prostaglandin 15d-PGJ2, the main
endogenous agonist of PPARg.
Conclusions: Our results demonstrate that, depending on duration, stress exposure elicits opposite effects on
PGE2/15d-PGJ2 ratios in spinal cord of EAE-induced Dark Agouti rats. Further studies are needed to elucidate if
these changes in prostaglandin balance are sufficient to mediate the differences in clinical score and inflammation
here reported, and to establish the potential utility of pharmacological intervention in MS directed toward anti-
inflammatory pathways.
Background
Multiple sclerosis (MS) is a chronic, disabling disease of
the central nervous system (CNS), affecting more than 2
million people worldwide. It has an autoimmune compo-
nent and is characterized by chronic neuroinflammation
with lymphocyte infiltration into the CNS, myelin loss,
gliosis, various degrees of axonal and oligodendrocyte
pathology and progressive neurological dysfunction [1].
Although the entire picture is still not clear, there are
several factors linked to higher risk of developing the
disease: 1) Genetics may play an important role and sev-
eral alleles have been identified as predisposing factors
for the disease, most of them related to the human leu-
kocyte antigen (HLA) system [2]; 2) the clinical and
pathological features of MS implicate viral infections as
either cofactors in its aetiology or as triggers for relapse
(especially Herpes and Epstein Barr viruses) [3,4]; 3) MS
is more prevalent in women than in men, suggesting
importance of hormones in its pathophysiology [5]; 4)
since the first description of MS, psychological stress
has been implicated in triggering exacerbations, and
some meta-analyses suggest a positive relationship
* Correspondence: bgomezpe@gmail.com
1Department of Pharmacology, Faculty Medicine, University Complutense,
Centro de Investigación Biomédica en red de Salud Mental (CIBERSA),
Granada, Spain
Full list of author information is available at the end of the article
Pérez-Nievas et al. Journal of Neuroinflammation 2010, 7:60
http://www.jneuroinflammation.com/content/7/1/60
JOURNAL OF 
NEUROINFLAMMATION
© 2010 Pérez-Nievas et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.between stressful events and higher risk for relapse [6]
and increased risk of new gadolinium-enhancing (Gd+)
brain lesions [7]. However, while studies of animal mod-
els have potential to explain the pathophysiological basis
of these interactions, data from these animal models are
inconsistent (reviewed in [8]): in general, acute stress
before inoculation increases the severity of the disease
[9,10], while chronic stress has been reported to have a
protective role, but only when applied prior to induction
of EAE [11-13]. However, data obtained from the Thei-
ler’s murine encephalomyelitis virus (TMEV) model are
sometimes contradictory and still inconclusive [14-17].
O nt h eo t h e rh a n d ,W h i t a c r ee ta l . ,( 1 9 9 8 )h a v es h o w n
that stress exposure after induction of relapsing EAE
has no protective effect [13].
The general response to stress includes release of glu-
cocorticoids as a consequence of activation of the
hypothalamic-pituitary-adrenal (HPA) axis. Glucocorti-
coids are considered to be anti-inflammatory, immuno-
suppressive and immunomodulatory in the periphery
under normal conditions. The mechanisms underlying
these peripheral effects include inhibition of lymphocyte
proliferation and dendritic cell maturation, as well as
apoptosis of basophils, eosinophils and T-cells [18].
However, in recent years, this classic view that glucocor-
ticoids are universally anti-inflammatory has been chal-
lenged, mainly in the CNS [19]. In particular, in the
brain, glucocorticoids are not uniformly anti-inflamma-
tory, and can even have pro-inflammatory actions on
functions such as cell extravasation and migration and
transcription factor activity [20], when released at supra-
physiological levels.
Indeed, exposure to restraint stress induces the release
of proinflammatory cytokines such as tumor necrosis
factor-a (TNFa) in the CNS, which activates inflamma-
tory nuclear transcription factor B- (NFB) dependent
pathways inducing expression of inducible NO synthase
(iNOS) and of the inducible form of cyclooxygenase
(COX2), among other inflammatory mediators [21]. The
result of these effects is the accumulation of proinflam-
matory, oxidative and nitrosative mediators (i.e. prosta-
glandin E2 (PGE2) and reactive oxidant species, such as
nitric oxide (NO) or peroxinitrite anion (ONOO
-)).
Some of these, being free radicals or highly reactive
compounds, can attack membrane phospholipids and
cause cell damage by lipid peroxidation [22].
Noticeable anti-inflammatory pathways are also acti-
vated in brain in response to immobilisation stress, con-
stituting a possible endogenous mechanism of defence
against excessive inflammation. One of the mechanisms
that enables “central neurogenic protection” [23] is acti-
vation of a cyclooxygenase subpathway, which leads to
an increase in levels of the anti-inflammatory prosta-
glandin 15deoxi-prostaglandin J2 (15d-PGJ2)a n dh e
activation of its main cellular target, peroxisome prolif-
erator-activated receptor gamma, PPARg [24,25].
PPARg and its agonists regulate cerebral physiology
and have been proposed as potential therapeutic targets
for the treatment of several pathological conditions
related with neuroinflammation within CNS; i.e. PPARg
agonists exert a broad spectrum of protective effects in
several animal models of neurological and cardiovascular
diseases (reviewed in [26]). In the case of EAE, PPARg
activation by both endogenous (15d-PGJ2) and synthetic
(thiazolidinediones) agonists ameliorates the pathophy-
siology of the disease, decreasing the clinical symptoms
by reducing inflammation [27-32].
Taking into account the above-described opposite
effects of stress exposure on the course of EAE, depend-
ing on the type of stress and the moment of its applica-
tion, we submitted EAE-induced Dark Agouti rats to
immobilisation stress ands t u d i e ds t r e s s - i n d u c e d
changes in EAE clinical signs, myelin loss, disruption of
brain blood barrier (BBB), leukocyte infiltration and
accumulation of inflammatory/oxidative mediators in
the spinal cord at two different time points: 12 and 21
days.
Methods
Animals
Forty eight young-adult (12-week old) male Dark Agouti
rats (DA/OlaHsd from Harlan Iberica) weighing 225-
250 g were used. All experimental protocols followed
the guidelines of the Animal Welfare Committee of the
Universidad Complutense according to European legis-
lation (2003/65/EC). Rats were housed individually
under standard conditions of temperature and humidity
and a 12-h light/dark cycle (lights on at 0800 h) with
free access to food and water. All animals were main-
tained under constant conditions for at least 7 days
prior to experiment.
Induction of EAE
Several different EAE models have been developed,
which differ in the grade and time of appearance of
immunological reactions and inflammatory processes
within the CNS. For this study, the EAE-inductor agent
chosen was myelin oligodendrocyte glycoprotein (MOG)
which is a unique myelin autoantigen as it is able to
induce not only an encephalitogenic T-cell response in
susceptible species, but also a demyelinating autoanti-
body response [33]. This specific model shows several
similarities to MS, such as a relapsing-remitting disease
course, demyelination, and axonal degeneration [34].
Rats were immunized subcutaneously at the base of the
tail with 150 μg of rat MOG peptide (fragment 35-55)
(Sigma, Madrid, Spain) emulsified in Freund’sa d j u v a n t
(Sigma) supplemented with 400 μg of heat-inactivated
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MI, USA)) to make complete Freund’sa d j u v a n t( C F A )
in a total volume of 100 μLp e rr a t .T h i sE A Em o d e l
mimics the relapsing-remitting disease course, which is
present in the majority of MS patients [35].
Animals were weighed and scored daily for signs of
EAE according to the following scale: 0, no disease; 1,
tail paralysis; 2, hind limb weakness; 3, hind limb paraly-
sis; 4, hind limb paralysis plus forelimb weakness; 5,
moribund or dead.
Stress model
Rats were exposed to 6 h of immobilisation stress
between 0900 and 1500 h in the animal homeroom for
21 or 12 days in two different sets of experiments starting
the same day of the inoculation with MOG in the case of
the EAE and stress group of animals. Another group of
animals was submitted to stress (21 or 12 days depending
on the experiment) and received only vehicle. Animals
from the control group were not immobilised and
received only vehicle. EAE animals were not stressed
after inoculation with MOG/CFA. Experimental groups
were: (1) control (Control n = 6); (2) stress for 21 or 12
days (S n = 6); (3) MOG/CFA-inoculated (EAE n = 6);
and (4) inoculated with MOG/CFA and submitted to
stress for 21 or 12 days (EAE+S n = 6). The experimental
design is shown in figure 1A. Restraint was performed
using a plastic rodent restrainer that allowed for a close
fit to rats during 6 h [36] in their home cages to mini-
mise the effects of the obligate social isolation when
placed in the individual restrainer. Animals were sacri-
ficed, still in the restrainer, immediately after restraint
using sodium pentobarbital (320 mg/Kg i.p.). Blood for
plasma determinations was collected by cardiac puncture
and anticoagulated in the presence of trisodium citrate
(3.15% w: v, 1 vol citrate per 9 vol blood). Spinal cord
was excised from the backbone and sections from the
thoracic and lumbar spinal cord were extracted and snap
frozen at -80°C until assayed.
Corticosterone levels
Corticosterone was measured at the end of the experi-
ment (day 21 or 12) in plasma from blood samples
obtained by cardiac puncture at 1500 h. After blood
centrifugation at 1,000 × g for 15 min, all plasma sam-
ples were stored at -80°C before assay using a commer-
cially available kit based on RIA with
125I-labeled rat
corticosterone (Siemens Healthcare Diagnostics S.L, Bar-
celona, Spain). A gamma counter (Wallac Wizard 1470,
Perkin Elmer, Waltham, MA, USA) was used to measure
radioactivity of the samples. The detection limit for the
kit is 5.7 ng/mL, the intra-assay coefficient of variation
is 4.3% and the interassay coefficient of variation is 5.8%.
Western blot analysis
After determination and adjusting protein levels, homo-
genates of spinal cord tissue, once centrifuged (12000 g,
20 min at 4°C) were mixed with Laemmli sample buffer
(Bio Rad, Hercules, CA, USA) (SDS 10%, distilled H2O,
glycerol 50%, Tris HCl 1M pH 6,8, dithiotreitol and
blue bromophenol) with beta mercapthoethanol (50 μL
per mL of Laemmli) and 20 μL( 2μg/μL) were loaded
into an electrophoresis gel. Once separated by molecular
weight, proteins from the gels were blotted onto a poly-
vinylidene difluoride membrane (Millipore, Bedford,
MA, USA) or nitrocellulose membrane (Amersham
Biosciences Europe GmbH, Friburg, Germany) by semi-
dry transfer system (Bio Rad) and they were incubated
with specific antibodies: (a) glucocorticoid receptor (GR)
antibody from Santa Cruz Biotechnology (Santa Cruz,
CA, USA) raised against an epitope mapping at the N-
terminus of GR a of mouse origin; (b) matrix metallo-
protease-9 (MMP-9) rabbit polyclonal antibody from
Chemicon generated using E. Coli-expressed active rat
92 kDa type IV collagenase (catalytic domain) as immu-
nogen. The dilution of the antibody was 1:1000 in TBS-
Tween; (c) myelin basic protein (MBP) rabbit polyclonal
antibody from Santa Cruz Biotechnology (Santa Cruz,
CA, USA) raised against amino acids 134-304 (deletion
193-218) of MBP of human origin in a dilution of
1:1000 in TBS-tween; (d) NOS-2 rabbit polyclonal anti-
body from Santa Cruz Biotechnology raised against a
peptide mapping at the amino terminus of NOS-2 of
h u m a no r i g i ni nad i l u t i o no f1 : 1 0 0 0i nT B S - T w e e n ;( e )
COX-2 goat polyclonal antibody from Santa Cruz Bio-
technology raised against a peptide mapping at the
C-terminus of COX-2 of human origin in a dilution of
1:750 in 5% skim milk in TBS-Tween; and (f) lipocalin
PGDS rabbit polyclonal antibody from Cayman (Cayman
Chemical Europe, Tallinn, Estonia) which recognizes
human lipocalin-type PGD synthase amino acids 30-41
(VQPNFQPDKFLG) in a dilution of 1: 500 in 5% skim
milk in TBS-Tween. As a loading control, mouse mono-
clonal b-actin antibody from Sigma was used. The
immunogen was a slightly modified b-cytoplasmic actin
N-terminal peptide, Ac-Asp-Asp-Asp-Ile-Ala-Ala-Leu-
Val-Ile-Asp-Asn-Gly-Ser-Gly-Lys, conjugated to KLH.
Proteins recognised by the antibody were visualised on
X - r a yf i l mb yc h e m i l u m i n i s c e n c e( E C L )f o l l o w i n gt h e
manufacturer’s instructions (Amersham lberica). Autora-
diographs were quantified by densitometry (program
Image J, NIH), and several time expositions were ana-
lysed to ensure the linearity of the band intensities.
Myeloperoxidase (MPO) activity assay
Immediately after sacrifice and dissection, spinal cord
samples were minced on ice and homogenized (glass/
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0.5% Nonidet P40 (Roche Farma, Madrid, Spain) in 20
mM phosphate buffer, pH 6.0. The homogenates were
then centrifuged for 20 min at 12,000 g. Tissue levels of
MPO activity were determined in supernatants using
hydrogen peroxide as a substrate for the enzyme. A unit
of MPO activity was defined as that converting 1 μmol
of hydrogen peroxide to water in 1 min at 40°C [37].
Lipid peroxidation
Lipid peroxidation rate was measured in spinal cord
homogenates by the thiobarbituric acid test for malonil-
dialdehyde (MDA) following the method described by Das
and Ratty (1987) with some modifications. Spinal cord
fragments were sonicated in 10 vol 50 mM phosphate buf-
fer and deproteinised with 40% trichloroacetic acid and 5
M HCl, followed by the addition of 2% (w/v) thiobarbituric
acid in 0.5 M NaOH. The reaction mixture was heated in
a water bath at 90°C for 15 min and centrifuged at
12,000×g for 10 min. The pink chromogen was measured
at 532 nm in a Beckman DU-7500 spectrophotometer
(Beckman Coulter, Madrid, Spain). The results are
expressed as nanomol per milligram of protein.
Prostaglandin levels
Spinal cord PGE2 and 15d-PGJ2 levels were determined
using enzyme immunoassay (EIA) kits (Cayman and
DRG Diagnostics, Marburg, Germany). Samples were
purified using Amprep
© minicolums (Amersham). After
homogenising spinal cord fragments by sonication
(Branson sonifier 250, American Lab Trading, East
Lyme, CT, USA) in PBS with Tris HCl, NaCl, glycerol,
1% Triton X100 and protease inhibitor cocktail, the
fraction needed for EIA was isolated and prostaglandin
quantification was carried out following the manufac-
turer’s instructions.
Figure 1 Chronic stress ameliorates MOG-induced EAE in DA rats. A Experimental design: one week after habituation of animals they were
inoculated with MOG/CFA (EAE and EAE+S groups), only with CFA (Control and S groups) and submitted (S and EAE+S groups) or not (Control
and EAE groups) to stress for 21 or 12 days depending on the experiment. B Clinical score in EAE-induced animals submitted or not to stress
according to this score: 0, no disease; 1, tail paralysis; 2, hind limb weakness; 3, hind limb paralysis; 4, hind limb paralysis plus forelimb weakness;
5, moribund or dead. Clinical signs appeared earlier in the EAE+S group, but at day 21 the clinical score for the EAE group was 1.88 vs 1.54 in
the EAE+S group. C Stress and EAE induced an increase in plasma corticosterone levels. D GR expression in spinal cord was increased by EAE
and stress, and the EAE+S group showed the highest expression. # p < 0,05 vs Control; ## p < 0,01 vs Control; *p < 0,05 vs EAE one way
ANOVA test followed by a Newman-Keuls (MOG: myelin oligodendrocyte glycoprotein; CFA: Complete Freunds Adjuvant; EAE: Experimental
Autoimmune Encephalomyelitis).
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Protein levels were measured using Bradford’sm e t h o d
based on the principle of protein-dye binding (Bradford,
1976).
Chemicals and statistical analyses
Unless otherwise stated, the chemicals were obtained
from Sigma. Data in text and figures are expressed as
mean ± SEM. Differences in biochemical parameters
between groups were tested by the one way ANOVA
test followed by a Newman-Keuls test once normality of
distribution was assed and due to the sample size. A p
value < 0.05 was considered statistically significant. As
there are actually two sets of experiments, it is not
acceptable to perform a two-way ANOVA and introduce
time of stress as a factor.
Results
Effect of chronic stress on EAE
Effect of stress on EAE onset and severity
As it can be observed in figure 1B, clinical signs
appeared earlier (days 5-8) in the EAE+S group than in
the EAE group (days 12-15). However, after 21 days of
experiment, animals from the EAE group showed higher
clinical score than those submitted to 6 hours of daily
immobilisation stress (EAE+S group) (1.88 vs 1.54, p <
0.05; according to following clinical score: 0, no disease;
1. tail paralysis; 2. hind limb weakness; 3. hind limb
paralysis; 4. hind limb paralysis plus forelimb weakness;
5. moribund or dead).
These data indicate that the 21-day-restraint animals
exhibit a significantly lower incidence of EAE clinical
signs, lower mean clinical score and lower cumulative
score. Thus prolonged restraint stress has a long-term
suppressive effect on disease, resulting in a significant
reduction in clinical score.
Effect of chronic stress and EAE on plasma corticosterone
levels
Since glucocorticoids have been closely associated with the
onset and severity of EAE, we measured corticosterone
plasma levels in the different groups. As expected, EAE
induced a significant increase in plasma corticosterone
levels on day 21 after inoculation with MOG/CFA (EAE:
451,1 ± 53,37 ng/mL vs control: 134,7 ± 21,16 ng/mL).
Chronic immobilisation stress had a similar effect on cor-
ticosterone levels (S: 388 ± 42,59 ng/mL). However, the
increase in plasma corticosterone in the group of animals
submitted to stress and inoculated with MOG/CFA was
not statistically different from the other groups (EAE+S:
425,8 ± 49,24 ng/mL) (figure 1C, F: 23,08, dF: 33). Analysis
of another indicator of HPA axis activity and regulation,
glucocorticoid receptor (GR) expression, showed an
increase in all groups of animals compared with their con-
trols, 21 days after the onset of experiment (figure 1D;
F: 14,74, dF: 7), indicating a normal regulation of the
HPA axis.
Effect of chronic stress and EAE on BBB permeability,
leukocyte infiltration and myelin levels in spinal cord
MMP-9 up-regulation has been associated with blood-
brain barrier (BBB) dysfunction in multiple neuropatho-
logical scenarios [38,39]. Western blot studies showed
that animals stressed for 21 days after inoculation with
MOG showed lower MMP-9 expression in spinal cord
than animals only inoculated with MOG (figure 2A; F:
2,332, dF: 13). This observation suggests a possible
higher degree of BBB disruption in EAE-induced ani-
mals than in EAE-induced animals submitted to chronic
stress.
Higher BBB disruption led to an increase in leukocyte
infiltration, measured by myeloperoxidase (MPO; H2O2
oxidoreductase) activity in spinal cord. MPO is an
enzyme found in the azurophilic granules of mammalian
neutrophils and also identified in human monocytes,
and its activity has already been taken as a marker of
leukocyte infiltration [40]. The EAE group showed
enhanced MPO activity compared to the control group
(9,66 ± 1,59 vs 5,59 ± 0,42 mU/min.mg protein respec-
tively: see figure 2B; F: 6,708, dF: 15) while no increase
in MPO activity was observed in the EAE group sub-
mitted to chronic stress, indicating leukocyte infiltration
in spinal cord of the EAE group, but not of the EAE+S
group, which could be directly related to the effects on
MMP-9 expression above mentioned.
Parallel to MMP-9 upregulation and MPO overactiv-
ity, the demyelinating lesion, assessed by myelin basic
protein (MBP) levels in spinal cord, was higher in the
EAE+S group than in EAE: Western blot analysis in fig-
ure 2C showed a consistent decrease in MBP levels in
spinal cord homogenates from the EAE group 21 days
after MOG inoculation, but not in EAE-induced animals
submitted to stress (EAE+S) (F: 10,17, dF: 13).
Oxidative parameters in spinal cord after EAE and chronic
stress protocol
Our next studies were aimed at elucidating the effects
of stress exposure on the neuroinflammatory/oxidative
process elicited by EAE in spinal cord of Dark Agouti
rats. Both EAE and chronic stress induced an increase
in iNOS expression compared with the control group
in spinal cord homogenates, as measured by western
blot. However, animals from the EAE group showed
higher iNOS expression compared to the EAE+S group
(figure 3A and densitometric analysis of the band of
interest: F: 24,54, dF: 16). This fact correlated with a
higher lipid peroxidation rate (determined by measur-
ing levels of MDA, a product derived from membrane
phospholipid attack) observed in spinal cord homoge-
nates of the EAE group (figure 3B) compared with
EAE+S (F: 92,15, dF: 13).
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spinal cord after EAE and stress: COX-2 and prostaglandins
As in the case of iNOS expression, both stress and
immunization with MOG/CFA induced an increase in
the expression of the inducible isoform of cyclooxygen-
ase (COX2) in spinal cord homogenates after 21 days.
Exposure to chronic stress reduced this increase of
expression, as can be observed in figure 4A (group EAE
+S compared to EAE: F: 5,032, dF: 7). However, there
were no significant differences in spinal cord levels of
proinflammatory PGE2, which is one of the products
derived from the activity of COX2, in none of the
groups studied (data not shown).
Conversely, as it can be observed in figure 4B, there
were differences in the levels of another COX2-derived
product: the anti-inflammatory prostaglandin 15d-PGJ2.
In fact, stress induced an increase in 15d-PGJ2 levels
(912,8 vs 638,7 pg/mg protein in control group). This
increase could also be observed in the EAE+S group
when compared to the EAE group (924,1 vs 427,7 pg/
mg protein: F: 6,897; dF: 26). These higher levels of
anti-inflammatory prostaglandin correlated with higher
expression of its specific enzymatic source, lipocalin
prostaglandin D synthase (PGDS) in the S and EAE+S
groups (western blot analysis in figure 4C with densito-
metric analysis of the band, F: 19,88, dF: 7). Twenty-one
days after EAE induction, stress may induce a shift of
anti-inflammatory/proinflammatory prostaglandin bal-
ance towards the former, which could have beneficial
effects.
Figure 2 Chronic stress reduces demyelination in MOG-EAE, MMP-9 expression and leukocyte infiltration. A Analysis of Matrix
metalloprotease 9 (MMP-9) expression in spinal cord by western blot and densitometric analysis of the band showed higher BBB disruption in
the EAE group than in the EAE+S group. (b actin expression was used as internal control) B MPO activity in spinal cord was increased in spinal
cord of EAE animals C Levels of MBP in spinal cord measured by western blot showed demyelination in the EAE group. b-Actin expression was
used as an internal control and densitometric analysis of the band of interest is shown below. *p < 0,05 vs EAE one way ANOVA test followed
by a Newman-Keuls.
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After the evaluation of the chronic stress results, a new
set of experiments was carried out to study the animals
on day 12, when the EAE+S group shows clinical signs
but the EAE group still does not (figure 1B). Clinical
signs were scored daily, as previously, and the same pat-
tern as in the other experiment was shown (figure is not
included to make reading easier). The EAE, S AND EAE
+S groups show increases in plasma corticosterone
levels similar to that seen after 21 days, with no signifi-
cant differences between them (figure 5A, F: 40,22,
dF:41). Interestingly, expression of GR in spinal cord
showed an opposite pattern to that in the 21-day experi-
ment, showing a lower expression in the EAE+S group
compared to the control group, which revealed differ-
ences in HPA axis regulatory mechanisms (figure 5B: F:
21,41, dF:7).
At day 12, MMP-9 expression was higher in the EAE
+S group compared to the EAE group (figure 5C:
F:405,1, dF:7), suggesting that stress could be enhan-
cing EAE-induced BBB dysfunction, in contrast to what
was observed on day 21. However, at this time point,
no demyelination was observed (figure 6A) and no dif-
ferences in levels of MBP in spinal cord homogenates
measured by western blot were observed. EAE and
stress increase expression of iNOS (figure 6B: F: 26,53,
d F :7 )a n d ,a l t h o u g ht h e r ei sat r e n dt o w a r dt h ei N O S
increase in expression to be higher in the EAE+S
group, there are no statistical differences when com-
pared to the EAE group. No differences in lipid peroxi-
dation in spinal cord rate were found for any of the
groups (figure 6C: levels of MDA). However, the
increase in COX2 expression was higher in the EAE+S
group compared to EAE, in contrast to what was
observed after 21 days (figure 7A). Moreover, at 12
days PGE2 levels were higher in the EAE+S group com-
pared with the other groups (3,887 pg/mg protein vs
0,4199 in control group, 0,9794 in stress group and
0.9165 in EAE group: F: 11,97, dF: 14, see figure 7B)
and no differences were found between groups in anti-
15d-PGJ2 levels (data not shown), suggesting a proin-
flammatory balance of prostaglandins for this time-
point of experiment that could account for the increase
in clinical score reported.
Discussion
The precise mechanisms through which stress regulates
susceptibility and severity of autoimmune diseases have
been extensively investigated. The biological impact of
stress is exerted via a feedback regulatory loop within a
network consisting of the central nervous system (CNS),
the endocrine system and the immune system. It has
already been established that effects of stress on
immune function are highly dependent on the type and
duration of the stressor [41]. Consequently, the effects
of stress on EAE development depend not only on type,
timing and duration of the stressor, but also on rat
strain and the chosen EAE model [6]. Repeated moder-
ate stressors may act by suppressing signs when given
before disease induction, whereas acute severe stressors
m a ye n h a n c et h ep r o g r e s s i o no fd i s e a s ea f t e ri t si n d u c -
tion [8]. The possibility that chronic stress reduces the
immunization response to MOG in the periphery, nega-
tively modulating CNS inflammatory responses, might
be a confounding factor in our study. However quantifi-
cation of plasma levels of IFNg, as a main peripheral
immune parameter in EAE, showed no differences
between groups (data not shown).
Figure 3 Chronic stress reduces the EAE-induced increase in inflammatory/oxidative status. A Western blot analysis revealed that iNOS
expression in spinal cord homogenates was higher in EAE than in the EAE+S group; b-actin was used as an internal control and densitometric
analysis of the band of interest is shown. B Lipid peroxidation rate measured by levels of MDA was also higher in spinal cord of the EAE group
compared to the EAE+S group. *p < 0,05 vs EAE; # p < 0,05 vs Control, one way ANOVA test followed by a Newman-Keuls.
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tion, stress exposure elicits opposite effects on the
proinflammatory PGE2/anti-inflammatory 15d-PGJ2 bal-
ance in spinal cord of EAE-induced Dark Agouti rats.
Exposure to 12 days of immobilisation stress induces a
consistent increase in PGE2, MMP-9 over-expression
and increased EAE clinical score. Conversely, chronically
stressed (21 days) EAE-induced DA rats show increased
15d-PGJ2 levels, amelioration of clinical score, and
reduced myelin loss, MMP-9 expression, MPO activity,
and accumulation of neuroinflammatory mediators in
the spinal cords of these animals. Further studies are
needed to elucidate whether these changes in prosta-
glandins balance are sufficient to mediate the differences
in clinical score and biochemical parameters here
reported in the different temporal paradigms.
Supporting the existence of a causal interaction, some
authors have established a relationship between acute
relapse and PGE2 and determined the roles of mPGES-1
and PGE2 in EAE by the AA cascade-targeted lipidomics
approach, and found that the PGE2 pathway is favoured
and the PGD2,P G I 2, and 5-Lipooxigenase pathways are
attenuated. Correlation analysis imply that the AA-pro-
ducing enzyme cPLA2 possibly passes more AA to COX
than the 5-LO pathway in EAE, because the sequential
actions of eicosanoid synthesizing enzymes are regulated
spatially and temporally in the cells, the so-called func-
tional coupling [42]. Likewise, PGH2, a common precur-
sor of PGs, appears to be selectively consumed by the
PGE2 pathway rather than the PGI2 and PGD2 pathways,
thereby producing PGE2 in the spinal cords of EAE mice
[43]. In fact, levels of proinflammatory/anti-inflammatory
Figure 4 The COX2 pathway is shifted towards anti-inflammatory mediators in EAE+S group. A COX2 expression measured by western
blot is lower in spinal cord of animals from the EAE+S group compared to the EAE group. B Chronic stress increased levels of the anti-
inflammatory prostaglandin 15d-PGJ2 in spinal cord. C. Expression of lipocalin PGD synthase, the final enzyme responsible for synthesis of 15d-
PGJ2 was also higher in spinal cord of the EAE+S group. b-Actin was used as internal control and densitometric analysis of the band of interest
is shown below. *p < 0,05 vs EAE;. # p < 0,05 vs Control, one way ANOVA test followed by a Newman-Keuls.
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Page 8 of 13PGs have already been shown to be regulated by each
other: previous studies have shown that 15d-PGJ2 is a
potent blocker of mPGE synthase mRNA induction by
LPS or IL-1b in macrophage-like differentiated U937
cells [44], fibroblasts and macrophages [45]. Similarly, we
have previously demonstrated that administration of
supraphysiological doses of 15d-PGJ2 can prevent the
release of PGE2 and COX2 increased expression after
stress exposure [24].
Some authors have directly implicated PGE2 in the
pathophysiology of EAE and others have used 15d-PGJ2
as an anti-inflammatory agent against the disease. In
this vein, PGE2 produced by microglia/macrophages
may aggravate EAE by promoting differentiation of Th1
and expansion of Th17 cells [46], with a consequent
increase of potentially deleterious proinflammatory cyto-
kines, as has been demonstrated in other inflammatory
scenarios [47,48].
On the other hand, PPARg activation by the adminis-
tration of 15d-PGJ2 ameliorates the pathophysiology of
the disease, decreasing the clinical symptoms by redu-
cing inflammation and blocking IL-12 dependent Th1
differentiation [30,49], and 15d-PGJ2 a n dr e t i n o i d×
receptor ligands exert additive anti-inflammatory effects
on another EAE model based on transgenic mice bear-
ing the rearranged Va2.3;Vh8.2 gene encoding the TCR
specific for the Ac1-11 peptide MBP [29]. Besides, 15d-
PGJ2 is also effective in inhibiting production of cyto-
toxic molecules, including nitric oxide (NO), TNFa and
interleukin 12, by microglial cells stimulated with inter-
feron (IFN) g and TNFa, molecules that have been
implicated in pathogenesis of EAE and MS [28], by
m e a n so fm e c h a n i s m st h a ta r eP P A R g-independent.
Regarding the inflammatory parameters analyzed in
our studies, 15d-PGJ2 administration inhibits MMP-9,
iNOS and COX-2 expression, MPO activity and MDA
Figure 5 Subchronic stress increases EAE-induced MMP-9 expression. A Again EAE and stress induced an increase in plasma corticosterone
but expression of GR in spinal cord measured by western blot revealed that the EAE+S group showed lower levels, indicating a failure in HPA
regulation (B). C MMP-9 expression in spinal cord by western blot showed an opposite pattern to that at day 21, with higher levels in the EAE+S
group than in the EAE group. b-Actin expression was used as an internal control and densitometric analysis of the band is shown below. *p <
0,05 vs EAE; # p < 0,05 vs Control, one way ANOVA test followed by a Newman-Keuls.
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Page 9 of 13Figure 6 No demyelination is observed at day 12 of the experiment and there are no differences in oxidative status in spinal cord of
the EAE and EAE+S groups. A Levels of MBP protein in spinal cord measured by western blot revealed no differences between the groups. B
iNOS expression in spinal cord is increased by EAE and stress, but there are no statistically significant differences between the EAE+S and EAE
groups. b-Actin expression was used as an internal control and densitometric analysis of the band is shown below. C Measurement of lipid
peroxidation rate in spinal cord showed no differences between groups. *p < 0,05 vs EAE;. # p < 0,05 vs Control, one way ANOVA test followed
by a Newman-Keuls.
Figure 7 Subchronic stress enhances proinflammatory PGE2 in EAE-induced DA rats. A COX2 expression was higher in spinal cord of the
EAE+S group at day 12, showing an opposite pattern to that at day 21, and (B) was correlated with higher levels of proinflammatory
prostaglandin in spinal cord. b-Actin expression was used as an internal control and densitometric analysis of the band is shown below *p <
0,05 vs EAE;. # p < 0,05 vs Control, one way ANOVA test followed by a Newman-Keuls.
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Page 10 of 13accumulation in inflammation-related pathologies such
as restraint stress exposure, cerebral ischaemia, and
colonic inflammation and dysfunction [24,50,51].
Here we demonstrate that shifting pathways towards
anti-inflammatory prostaglandins by chronic stress
e x p o s u r em a ya c t u a l l yb eb e n e f i c i a lf o rt h ec o u r s eo f
EAE, which is in accordance with the studies presented
above. More importantly it would provide support to
potential pharmacological modulation of PPARg/15d-
PGJ2 pathway or other anti-inflammatory strategies
in MS.
Immobilization stress differentially modulates the pro-
gression and outcome of EAE, but the underlying bio-
chemical mechanisms that explain the effects of brief
exposure to stress aggravating EAE disease are not com-
pletely understood. In addition to increased levels of
proinflammatory PGE2 that could modulate Th cell
activity, the data obtained here suggest that subchronic
stress could disrupt BBB integrity by enhancing MMP-9
expression (MMPs can influence expansion of the extra-
cellular matrix of the BBB and loosening of intercellular
tight junctions between endothelial cells through proteo-
lytic degradation) and, as an increase in BBB permeabil-
ity occurs prior to observable cellular infiltration in EAE
[52], this may lead to an earlier appearance of clinical
signs in stressed and inoculated animals. Chandler et al
(2002) have already proposed that stress has a profound
effect on the BBB, modulating EAE and MS. They
hypothesized that while chronic stress may have inhibit-
ing effects, acute stress may be disease-enhancing [9].
Results obtained from our different stress protocols
indicate that physiological response to stress consists, in
the case of this disease, also in a double, biphasic
response: stress applied from the moment of inoculation
with MOG provokes an earlier onset of disease, but
longer exposure to stress makes the disease less severe.
An adequate HPA response is necessary for correct con-
trol of disease; in fact, rat strains with a blunted HPA
response are more vulnerable to EAE. However, elevated
HPA activation in MS patients has been shown: in one
study patients with MS had significantly higher plasma
cortisol levels at baseline compared to matched controls.
Despite this hypercortisolism, patients with MS showed
normal, rather than blunted, plasma ACTH responses to
ovine CRH, suggesting that the pathophysiology of
hypercortisolism in MS is different from that in depres-
sion. Patients with MS also show blunted ACTH
response to AVP stimulation, and normal cortisol
response to high- and low-dose ACTH stimulation [53].
In the periphery, glucocorticoids inhibit innate and
adaptative responses, thereby inhibiting lymphocyte pro-
liferation and apoptosis of basophils and eosinophils, eli-
citing a redistribution of T cells and making dendritic
cells stay in an immature state. Stress hormones have
been implicated in reducing lymphocyte proliferation
and NK cell activity, cytokine, and antibody production
[54]. These facts turn out to be beneficial in the course
of EAE disease [20]. Besides, it has been established that
in EAE the HPA axis is activated in during clinical
exacerbations, and that levels of corticosterone decrease
as clinical signs remit [55]. However, there is emerging
evidence that GC sensitivity of immune cells is impaired
in MS [56]: while the HPA axis responds to inflamma-
tion during relapses [57], this response may be insuffi-
cient to control the inflammation
In our study, stress and EAE increased plasma levels
of corticosterone and there were no differences between
groups at the moment of sample extraction. However, it
is to be noted that in the EAE+S group a daily glucocor-
ticoid response was induced, as stress exposure started
at the same time as administration of MOG and this
was repeated until the day of sample extraction. More-
over, glucocorticoid receptor expression in spinal cord is
lower in the EAE+S group at 12 days than in the control
group, indicating a possible dysregulation of HPA feed-
back regulation (high levels of corticosterone not corre-
lated with increased expression of GR) which indicates
that hypofunction of the axis increases vulnerability and
severity of EAE. It is to be noted that, although it has
been proposed as the best animal model for MS, EAE
has been recently criticised because numerous therapeu-
tical approaches that showed promising results in this
model in the end turned out to be either inefficient or
in some cases harmful in human MS [58]. The results
obtained from this animal model have to be considered
carefully, but they may serve to understand the mechan-
isms and possible pharmacological modulation in MS
and they clearly demonstrate an effect of stress exposure
in the course of disease.
Conclusions
In summary, immobilisation stress exposure paradigms
differently modulate EAE pathophysiology at the clinical
level and allow the identification of and dynamic regula-
tion of possible biochemical pathways implicated in the
degenerative process of the disease, opening new ave-
nues for therapeutical strategies for MS (always consid-
ering the limitations of the EAE model). Further
complementary studies are needed to elucidate the role
of stress exposure in the aetiology and outcome of MS
and the intrinsic mechanisms implicated.
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